ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1788

TSLP Induces TNFα Production by CD1c Myeloid Dendritic Cells and Myeloid DC-Activated T Cells From Rheumatoid Arthritis Patients

F.M. Moret1, T.R.D.J. Radstake2, J.W.J. Bijlsma1, F.P.J.G. Lafeber1 and J.A.G. van Roon3, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, dendritic cells and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Fibroblasts from rheumatoid arthritis (RA) patients produce TSLP upon TLR and TNFα stimulation. Recently, we have shown that increased intra-articular TSLP concentrations in RA patients potently activate TSLPR-expressing mDCs from peripheral blood (PB) and synovial fluid (SF) of RA patients to secrete T cell attractant chemokines and to potently increase T cell activation. In addition, TSLP and its receptor play a crucial role in promoting Th17-driven collagen-induced arthritis. Since TNFα is a crucial pro-inflammatory and tissue-destructive mediator in RA, we assessed the capacity of TSLP to regulate TNFα production by CD1c mDCs and CD4 T cells in RA patients as compared to healthy controls (HC).

Methods: CD1c mDCs, isolated from PB as well as SF of RA patients (n=6), were stimulated with TSLP for 20 hours and TNFα production was measured by multiplex immunoassay. Washed TSLP-activated CD1c mDCs from PB (n=13) and SF (n=5) of RA patients and from PB of HC (n=5) were added to autologous CD4 T cells in the absence of additional stimuli, cultured for 6 days and subsequently proliferation was measured. Additionally, T-cell TNFα production was measured by ELISA upon restimulation with ionomycin/PMA.

Results: TSLP significantly stimulated the production of TNFα by mDCs from PB and SF (PB from 99 to 378 pg/ml, p<0.03 and SF from 170 to 355 pg/ml, p<0.03). Upon incubation with TSLP, TSLPR-expressing mDCs from PB potently stimulated proliferation of autologous CD4 T cells as compared to unstimulated mDCs (ratio T cell:DC 5:1, from 1503 to 16036 cpm, p<0.01). TSLP-mDCs from SF had a strongly increased capacity to activate CD4 T cells (ratio T cell:DC 5:1, from 26395 to 57387 cpm, p<0.05). Enhanced proliferation was associated with increased production of TNFα (ratio T cell:DC 5:1, PB from 3498 to 9225 pg/ml, p=0.001 and SF from 8951 to 18415 pg/ml, p<0.05). TNFα production by TSLP-mDC activated T cells from PB of RA patients was higher as compared to HC (RA from 3498 to 9225 pg/ml and HC from 3522 to 5686 pg/ml), although this was not statistically significant.

Conclusion: TSLP potently induces TNFα production by CD1c mDCs and mDC-activated CD4 T cells from RA patients. Considering the fact that TNFα can induce TSLP secretion by synovial fibroblasts this suggests a novel positive feedback loop of TNFα and TSLP that contributes to immunopathology of RA.


Disclosure:

F. M. Moret,
None;

T. R. D. J. Radstake,
None;

J. W. J. Bijlsma,
None;

F. P. J. G. Lafeber,
None;

J. A. G. van Roon,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tslp-induces-tnf%ce%b1-production-by-cd1c-myeloid-dendritic-cells-and-myeloid-dc-activated-t-cells-from-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology